145 related articles for article (PubMed ID: 32023597)
1. [Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
Rinsho Ketsueki; 2020; 61(1):20-26. PubMed ID: 32023597
[TBL] [Abstract][Full Text] [Related]
2. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Trudel S; Tessoulin B; Jullien M; Blin N; Gastinne T; Mahé B; Dubruille V; Bonnet A; Lok A; Chevallier P; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1441-1447. PubMed ID: 30874851
[TBL] [Abstract][Full Text] [Related]
3. [Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
Oka S; Takeuchi S; Shiragami H; Shimazu Y; Shimazu Y; Nougawa M
Gan To Kagaku Ryoho; 2018 Dec; 45(12):1779-1782. PubMed ID: 30587741
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.
Park H; Byun JM; Yoon SS; Koh Y; Yoon SW; Shin DY; Hong J; Kim I
PLoS One; 2022; 17(1):e0260113. PubMed ID: 35085238
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O; Parekh S; Cho HJ; Vishnuvardhan N; Madduri D; Richter J; Ip C; Lau K; Florendo E; Mancia IS; Thomas J; Verina D; Chan E; Zarychta K; La L; Strumolo G; Melnekoff DT; Leshchenko VV; Kim-Schulze S; Couto S; Wang M; Pierceall WE; Thakurta A; Laganà A; Jagannath S; Chari A
Leuk Lymphoma; 2020 Sep; 61(9):2208-2215. PubMed ID: 32812822
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Richter J; Biran N; Duma N; Vesole DH; Siegel D
Hematol Oncol; 2017 Jun; 35(2):246-251. PubMed ID: 27018162
[TBL] [Abstract][Full Text] [Related]
7. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
Short KD; Rajkumar SV; Larson D; Buadi F; Hayman S; Dispenzieri A; Gertz M; Kumar S; Mikhael J; Roy V; Kyle RA; Lacy MQ
Leukemia; 2011 Jun; 25(6):906-8. PubMed ID: 21350560
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Hoy SM
Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
[TBL] [Abstract][Full Text] [Related]
10. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Gao W; An N; Chen SL
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
Kauer J; Sester LS; Kriegsmann K; Weinhold N; Ober M; Müller-Tidow C; Goldschmidt H; Raab MS; Sauer S
Hematol Oncol; 2023 Aug; 41(3):453-462. PubMed ID: 36680428
[TBL] [Abstract][Full Text] [Related]
12. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma].
Gu Y; Yuan YH; Shi QL; Qu XY; Xu J; Guo R; Xu JD; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):279-284. PubMed ID: 28468087
[No Abstract] [Full Text] [Related]
15. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
[TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
Kawamura S; Tamaki M; Nakamura Y; Kawamura M; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Okada Y; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Kimura SI; Nakasone H; Kako S; Kanda Y
Acta Haematol; 2022; 145(5):553-559. PubMed ID: 35605591
[TBL] [Abstract][Full Text] [Related]
17. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Ahn SY; Jung SH; Joo YD; Lee WS; Lee SM; Choi CW; Kim SJ; Kim K; Lee JJ;
Ann Hematol; 2014 Sep; 93(9):1571-7. PubMed ID: 24728664
[TBL] [Abstract][Full Text] [Related]
18. Practical Considerations in Managing Relapsed Multiple Myeloma.
Agarwal A; Chow E; Bhutani M; Voorhees PM; Friend R; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):69-77. PubMed ID: 27986429
[TBL] [Abstract][Full Text] [Related]
19. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
[TBL] [Abstract][Full Text] [Related]
20. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
